Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersOphthalmology Physician in Boston, MA
NPI: 1366483778Primary Practice Location
TUFTS MEDICAL CENTER
755 Washington St, Boston, MA
Primary Employer
Pratt Ophthalmology Associates Inc
tuftsmedicine.org
HQ Phone
Get M.D. Pedram's Phone NumberMobile
Get M.D. Pedram's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 275 | 486 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 75 | 92 |
| 3 | 92132Imaging of front third of eye | 72 | 86 |
| 4 | 92014Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | 32 | 33 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 32 | 35 |
Reduced Corneal Endothelial Cell Density in Patients With Dry Eye Disease.
Authors: Ujwala Saboo, Thomas Dohlman, Ahmad Kheirkhah
Publication Date: 2014-09-24
Topical Cryopreserved Amniotic Membrane and Umbilical Cord Eye Drops Promote Re-Epithelialization in a Murine Corneal Abrasion Model.
Authors: Sean Tighe, Hamid-reza Moein, Lorraine Chua, Anny Cheng, Pedram Hamrah, Scheffer C Tseng
Publication Date: 2017-03-14
Authors: Benjamin Strauss
Journal: Cornea
Lead Sponsor: Tufts Medical Center
Collaborators: Ocular Therapeutix, Inc.
Intervention / Treatment: DRUG: Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg), OTHER: ProLong™ collagen plugs
Lead Sponsor: Tufts Medical Center
Intervention / Treatment: DEVICE: TrueTear™ intranasal neurostimulator (ITN)
Lead Sponsor: Oyster Point Pharma, Inc.
Intervention / Treatment: DRUG: OC-01 (varenicline) nasal spray, DRUG: Placebo (vehicle control) nasal spray
